Mirum Pharmaceuticals, Inc.
MIRM
$43.45
$0.912.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 336.89M | 307.03M | 264.38M | 224.00M | 186.37M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 336.89M | 307.03M | 264.38M | 224.00M | 186.37M |
| Cost of Revenue | 81.64M | 83.88M | 73.31M | 59.89M | 47.04M |
| Gross Profit | 255.25M | 223.15M | 191.07M | 164.11M | 139.34M |
| SG&A Expenses | 202.22M | 191.58M | 177.56M | 161.30M | 145.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 424.49M | 403.00M | 372.81M | 332.47M | 295.53M |
| Operating Income | -87.61M | -95.97M | -108.43M | -108.47M | -109.15M |
| Income Before Tax | -86.91M | -97.98M | -107.43M | -157.15M | -162.42M |
| Income Tax Expenses | 1.03M | 1.83M | 1.73M | 1.41M | 991.00K |
| Earnings from Continuing Operations | -87.94 | -99.81 | -109.16 | -158.56 | -163.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.94M | -99.81M | -109.16M | -158.56M | -163.42M |
| EBIT | -87.61M | -95.97M | -108.43M | -108.47M | -109.15M |
| EBITDA | -63.98M | -72.90M | -88.76M | -93.32M | -98.33M |
| EPS Basic | -1.86 | -2.23 | -2.51 | -3.93 | -4.19 |
| Normalized Basic EPS | -1.15 | -0.62 | -0.79 | -0.88 | -1.05 |
| EPS Diluted | -1.86 | -2.23 | -2.51 | -3.93 | -4.19 |
| Normalized Diluted EPS | -1.15 | -0.62 | -0.79 | -0.88 | -1.05 |
| Average Basic Shares Outstanding | 189.47M | 182.83M | 176.15M | 167.02M | 157.77M |
| Average Diluted Shares Outstanding | 189.47M | 182.83M | 176.15M | 167.02M | 157.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |